Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash from Financing Activities (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Cash from Financing Activities for 11 consecutive years, with $136000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 76.31% to $136000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $816000.0 through Dec 2025, down 99.28% year-over-year, with the annual reading at $816000.0 for FY2025, 99.28% down from the prior year.
  • Cash from Financing Activities hit $136000.0 in Q4 2025 for Voyager Therapeutics, up from $85000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $112.9 million in Q1 2024 to a low of $12000.0 in Q1 2022.
  • Historically, Cash from Financing Activities has averaged $7.9 million across 5 years, with a median of $331000.0 in 2023.
  • Biggest five-year swings in Cash from Financing Activities: soared 260783.33% in 2023 and later tumbled 99.93% in 2025.
  • Year by year, Cash from Financing Activities stood at $227000.0 in 2021, then increased by 21.59% to $276000.0 in 2022, then soared by 66.67% to $460000.0 in 2023, then grew by 24.78% to $574000.0 in 2024, then crashed by 76.31% to $136000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for VYGR at $136000.0 in Q4 2025, $85000.0 in Q3 2025, and $513000.0 in Q2 2025.